- Home
- RYN vs KRYS Comparison
RYN vs KRYS Comparison
Compare RYN & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- KRYS
- Stock Information
- Founded
- RYN 1926
- KRYS 2015
- Country
- RYN United States
- KRYS United States
- Employees
- RYN N/A
- KRYS N/A
- Industry
- RYN Real Estate Investment Trusts
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYN Real Estate
- KRYS Health Care
- Exchange
- RYN Nasdaq
- KRYS Nasdaq
- Market Cap
- RYN 3.5B
- KRYS 3.8B
- IPO Year
- RYN N/A
- KRYS 2017
- Fundamental
- Price
- RYN $23.61
- KRYS $148.15
- Analyst Decision
- RYN Hold
- KRYS Strong Buy
- Analyst Count
- RYN 4
- KRYS 10
- Target Price
- RYN $27.75
- KRYS $205.50
- AVG Volume (30 Days)
- RYN 1.2M
- KRYS 369.4K
- Earning Date
- RYN 08-06-2025
- KRYS 08-04-2025
- Dividend Yield
- RYN 12.27%
- KRYS N/A
- EPS Growth
- RYN 108.38
- KRYS 109.01
- EPS
- RYN 2.33
- KRYS 4.16
- Revenue
- RYN $1,233,027,000.00
- KRYS $333,448,000.00
- Revenue This Year
- RYN N/A
- KRYS $44.05
- Revenue Next Year
- RYN $3.99
- KRYS $46.15
- P/E Ratio
- RYN $10.09
- KRYS $35.53
- Revenue Growth
- RYN 17.89
- KRYS 247.53
- 52 Week Low
- RYN $21.84
- KRYS $122.80
- 52 Week High
- RYN $32.88
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- RYN 56.66
- KRYS 59.74
- Support Level
- RYN $22.59
- KRYS $139.20
- Resistance Level
- RYN $23.89
- KRYS $151.48
- Average True Range (ATR)
- RYN 0.52
- KRYS 5.30
- MACD
- RYN 0.15
- KRYS 1.29
- Stochastic Oscillator
- RYN 88.29
- KRYS 79.97
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.